I wonder about that, Harry. Maybe they will be, but will they be monitored for the correct risks?I suppose these patients will be monitored far more carefully after what happened with Tysabri.
I think I'll go ahead and start a new thread on the research I did with regard to daclizumab. Might as well. Since when do I mind getting Biogen in a uproar?

Deb